Stock Alert: Co-Diagnostics Up 15% On COVID-19 Test Approval

(RTTNews) - Shares of Co-Diagnostics, Inc. (CODX) jumped 15% on Monday morning after the company announced it received FDA's emergency use authorization for its Covid-19 test.

CODX is currently trading at $27.49, up $3.49 or 14.55%, on the Nasdaq.

Co-Diagnostics said its partner, Clinical Reference Laboratory has FDA Emergency Use Authorization for CRL Rapid Response, a saliva-based COVID-19 test that can be self-administered at home, work or any other setting and then tested using Co-Diagnostics' patented CoPrimer technology.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.